Literature DB >> 26854881

Coagulopathy and its management in patients with severe burns.

G J Glas1, M Levi2, M J Schultz1,3.   

Abstract

Severe burn injury is associated with systemic coagulopathy. The changes in coagulation described in patients with severe burns resemble those found patients with sepsis or major trauma. Coagulopathy in patients with severe burns is characterized by procoagulant changes, and impaired fibrinolytic and natural anticoagulation systems. Both the timing of onset and the severity of hemostatic derangements are related to the severity of the burn. The exact pathophysiology and time course of coagulopathy are uncertain, but, at least in part, result from hemodilution and hypothermia. As the occurrence of coagulopathy in patients with severe burns is associated with increased comorbidity and mortality, coagulopathy could be seen as a potential therapeutic target. Clear guidelines for the treatment of coagulopathy in patients with severe burns are lacking, but supportive measures and targeted treatments have been proposed. Supportive measures are aimed at avoiding preventable triggers such as tissue hypoperfusion caused by shock, or hemodilution and hypothermia following the usually aggressive fluid resuscitation in these patients. Suggested targeted treatments that could benefit patients with severe burns include systemic treatment with anticoagulants, but sufficient randomized controlled trial evidence is lacking.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  anticoagulants; blood coagulation; burn; critical care; disseminated intravascular coagulation; fibrinolysis

Mesh:

Substances:

Year:  2016        PMID: 26854881     DOI: 10.1111/jth.13283

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

Review 1.  Burn management during the COVID-19 pandemic: recommendations and considerations.

Authors:  Amjad Soltany; Ali Ramez Hasan; Farah Mohanna
Journal:  Avicenna J Med       Date:  2020-10-13

Review 2.  Modern Aspects of Burn Injury Immunopathogenesis and Prognostic Immunobiochemical Markers (Mini-Review).

Authors:  Tatyana A Kuznetsova; Boris G Andryukov; Natalia N Besednova
Journal:  BioTech (Basel)       Date:  2022-05-27

3.  Antithrombin use and 28-day in-hospital mortality among severe-burn patients: an observational nationwide study.

Authors:  Takashi Tagami; Hiroki Matsui; Yuuta Moroe; Reo Fukuda; Ami Shibata; Chie Tanaka; Kyoko Unemoto; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Ann Intensive Care       Date:  2017-02-20       Impact factor: 6.925

Review 4.  Measuring coagulation in burns: an evidence-based systematic review.

Authors:  Nicholas J Marsden; Martin Van; Samera Dean; Ernest A Azzopardi; Sarah Hemington-Gorse; Phillip A Evans; Iain S Whitaker
Journal:  Scars Burn Heal       Date:  2017-09-05

5.  Nebulized heparin for inhalation injury in burn patients: a systematic review and meta-analysis.

Authors:  Xiaodong Lan; Zhiyong Huang; Ziming Tan; Zhenjia Huang; Dehuai Wang; Yuesheng Huang
Journal:  Burns Trauma       Date:  2020-06-04

6.  Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.

Authors:  Juan Hu; Yong-Hong Xiao; Yi Zheng; Yang-Xiao Lai; Xue-Ling Fang; Qiang Fang
Journal:  Eur J Clin Pharmacol       Date:  2020-04-30       Impact factor: 2.953

Review 7.  Burn-Induced Coagulopathies: a Comprehensive Review.

Authors:  Robert L Ball; John W Keyloun; Kathleen Brummel-Ziedins; Thomas Orfeo; Tina L Palmieri; Laura S Johnson; Lauren T Moffatt; Anthony E Pusateri; Jeffrey W Shupp
Journal:  Shock       Date:  2020-08       Impact factor: 3.533

8.  Plasmin drives burn-induced systemic inflammatory response syndrome.

Authors:  Breanne H Y Gibson; Colby C Wollenman; Stephanie N Moore-Lotridge; Patrick R Keller; J Blair Summitt; Alexey R Revenko; Matthew J Flick; Timothy S Blackwell; Jonathan G Schoenecker
Journal:  JCI Insight       Date:  2021-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.